Search by GESP name  
   

 

ERBB3  
    


    
      Official symbol:  ERBB3
      Full name:  erb-b2 receptor tyrosine kinase 3
      Location:  12q13.2
      Also known as:  HER3, LCCS2
      Entrez ID:  2065
      Ensembl ID:  ENSG00000065361
      Summary:  This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized. [provided by RefSeq, Jul 2008]

    

    
  Overall distribution
    
  Tissue specific distribution
    
 
  
 
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Gscore (Amp):  0.22  
Gscore (Del):  0.00  
 
Recurrently amplified in 1 cancer type(s)
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Mscore:  0.60  (Driver)
 
Recurrently mutated in 3 cancer type(s)
   

    
  Overall
    
  Tissue specific
    
 
Total fusion occurrence:  23  (Driver)
 
Fusions detected in 12 cancer type(s)
 
 

    
  Overall
    
  Tissue specific
    
   STRONGLY SELECTIVE     
   

    
      Functional class:  Kinase (protein kinase)
      JensenLab PubMed score:  870.28  (Percentile rank: 94.66%)
      PubTator score:  726.05  (Percentile rank: 95.32%)
      Target development/druggability level:  TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below.
      Tractability (small molecule):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets
      Tractability (antibody):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets

    







Contact us | | Terms & Conditions.
Copyright © 2020 University of Pennsylvania. All Rights Reserved.